Premium
High antiviral activity of NS 5A inhibitor ABT ‐530 with paritaprevir/ritonavir and ribavirin against hepatitis C virus genotype 3 infection
Author(s) -
Poordad Fred,
Landis Charles S.,
Asatryan Armen,
Jackson Daniel F.,
Ng Teresa I.,
Fu Bo,
Lin ChihWei,
Yao Betty,
Kort Jens
Publication year - 2016
Publication title -
liver international
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.873
H-Index - 110
eISSN - 1478-3231
pISSN - 1478-3223
DOI - 10.1111/liv.13067
Subject(s) - ritonavir , ribavirin , ombitasvir , paritaprevir , medicine , adverse effect , virology , pharmacology , hepatitis c virus , gastroenterology , viral load , virus , antiretroviral therapy
Background & Aims ABT ‐530 is a next‐generation hepatitis C virus ( HCV ) NS 5A inhibitor with potent pangenotypic antiviral activity in vitro . Paritaprevir is an NS 3/4A protease inhibitor codosed with ritonavir that displays in vitro activity against HCV genotypes 1–4 and 6. Methods Efficacy, pharmacokinetics and safety of ABT ‐530 with paritaprevir/ritonavir and ribavirin were evaluated in this phase 2, open‐label, multicentre study in treatment‐naïve non‐cirrhotic patients with genotype 3 infection. Ten patients, all genotype 3a, received 120 mg ABT ‐530 and 150/100 mg paritaprevir/ritonavir once daily with ribavirin for 12 weeks. Results Nine (90%) patients achieved a sustained virological response at post‐treatment weeks 12 and 24. One patient experienced virological failure at treatment week 6. Sequence analyses for HCV variants in samples from this patient identified A166S in NS 3 at baseline and after breakthrough, as well as A30K at baseline and linked S24F+M28K+A30K variants in NS 5A after breakthrough. Neither genotype 3 NS 3 A166S nor NS 5A A30K variant confers any resistance to paritaprevir or ABT ‐530 respectively. However, genotype 3 NS 5A S24F+M28K+A30K‐linked variant confers a >5000‐fold increase in ABT ‐530 EC 50 relative to that of the wild‐type replicon. This patient's ABT ‐530 exposure was comparable to the cohort, while paritaprevir and ritonavir exposures were the lowest of all patients. No serious or severe adverse events and adverse events leading to early discontinuation were reported. Conclusions Results from this study show that ABT ‐530 holds promise as part of a direct‐acting antiviral treatment regimen for HCV genotype 3 infection.